NeoGenomics establishes Biomarker Assist KRAS Single Gene Testing Program for advanced NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NeoGenomics Inc., a provider of cancer-focused genetic testing services and global oncology contract research services, has launched an Amgen-sponsored testing program to support single-gene molecular testing for the biomarker KRAS G12C for eligible lung cancer patients at no cost to the patient.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login